Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Primary diagnosis of OCD

• Currently on a stable and adequate dose of an SRI

• Sufficient severity of symptoms to warrant additional augmentation treatment

Exclusion Criteria:

• Medical or psychiatric conditions that would make participation in the study unsafe

• Currently receiving psychotherapy elsewhere at the time of study entry

• Previously (within 12 weeks prior to study entry) attended 8 or more sessions of EX/RP within a 2-month period or received at least 4 weeks of antipsychotic augmentation while on an adequate SRI dose

• Currently being treated with an SRI for the first time and has not yet responded, but has not tried another SRI